Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis (Q44060078)

29 November 2017

Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis (English)

1 reference

experimental autoimmune encephalomyelitis

29 November 2017

0 references

4

Celia F Brosnan

1 reference

29 November 2017

Douglas L Feinstein

1

1 reference

29 November 2017

Elena Galea

2

1 reference

29 November 2017

Vitaliy Gavrilyuk

3

1 reference

29 November 2017

Caroline C Whitacre

5

1 reference

29 November 2017

Lucia Dumitrescu-Ozimek

6

1 reference

29 November 2017

Gary E Landreth

7

1 reference

29 November 2017

Harrihar A Pershadsingh

8

1 reference

29 November 2017

Guy Weinberg

9

1 reference

29 November 2017

Michael T Heneka

10

1 reference

29 November 2017

1 June 2002

1 reference

29 November 2017

1 reference

29 November 2017

51

1 reference

29 November 2017

694-702

1 reference

29 November 2017

6

1 reference

Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis

29 November 2017

1 reference

Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system

21 January 2018

1 reference

Cytokine-directed therapies in multiple sclerosis and experimental autoimmune encephalomyelitis

21 January 2018

1 reference

Cuprizone and piperonyl butoxide, proposed inhibitors of T-cell function, attenuate experimental allergic encephalomyelitis in SJL mice

21 January 2018

1 reference

Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression.

21 January 2018

1 reference

Treatment of multiple sclerosis: recent trials and future perspectives

21 January 2018

1 reference

Evaluation of mitoxantrone for the treatment of multiple sclerosis

21 January 2018

1 reference

Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology

21 January 2018

1 reference

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

21 January 2018

1 reference

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression

21 January 2018

1 reference

Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300.

21 January 2018

1 reference

Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells

21 January 2018

1 reference

Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT.

21 January 2018

1 reference

The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis

21 January 2018

1 reference

PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture.

21 January 2018

1 reference

The heat shock response reduces myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in mice.

21 January 2018

1 reference

Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis

21 January 2018

1 reference

Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators

21 January 2018

1 reference

A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response

21 January 2018

1 reference

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies

21 January 2018

1 reference

Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury

21 January 2018

1 reference

Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation

21 January 2018

1 reference

Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.

21 January 2018

1 reference

Immunologic therapy of multiple sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ANA.10206

1 reference

29 November 2017

1 reference